SCHEMBL1260122

SCHEMBL1260122

CC1CCNC(=O)N1c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 1/20 0.44
CRY2 Q49AN0 1/20 0.44
HSD11B1 P28845 1/20 0.41
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
ALDH1A1 P00352 4/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 1/20 0.37
HTR7 P34969 2/20 0.36
GFER P55789 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5314594 0.80 SIRT6 (0.46) ALDH1A1MAPTGFERMEN1KMT2A
SCHEMBL16480393 0.76 TDP1 (0.47) PER2CRY2HSD11B1SLC6A2SLC6A4
SCHEMBL362984 0.68
SCHEMBL305860 0.67 ALDH1A1 (0.55) ALDH1A1POLBMAPK1MAPTGFER
SCHEMBL8465310 0.67 HSD11B1 (0.47) HSD11B1MAPK1HTR7GFERMEN1
SCHEMBL8305787 0.67 GAA (0.46) POLBMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL29327276 0.66 HTR2C (0.41)
SCHEMBL16701852 0.66 DDB1 (0.39) PER2CRY2ALDH1A1POLBMAPK1
SCHEMBL2234874 0.65 GAA (0.44) ALDH1A1POLBMAPTGFERMEN1
SCHEMBL31663152 0.65 GAA (0.44) ALDH1A1POLBMAPTGFERMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF ABL1, MAP4K2, MAP3K20 PER2 3744/4885CRY2 4193/4885HSD11B1 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.